How to drug a novel target in 500 molecules
Research conducted by the Variational AI team: Marshall Drew-Brook, Peter Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, and Ali Saberali. Searching through the space of synthesizable molecules to find an… Read More about How to drug a novel target in 500 molecules
Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™Lead Generator to discover first-in-class cancer drugs. Read More about Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Why is QSAR so far behind other forms of machine learning, and what can be done to close the gap?
QSAR models struggle with extrapolation compared to conventional ML tasks like image recognition. Machine learning generalizes effectively when structured to align with its problem domain, suggesting that improving QSAR models… Read More about Why is QSAR so far behind other forms of machine learning, and what can be done to close the gap?
100 AI-generated molecules are worth a 1,000,000 molecule high-throughput screen
Generative AI in drug discovery is showing promise by optimizing molecule searches beyond traditional methods. Variational AI’s Enki algorithm created 100 AI-generated molecules that outperform 1,000,000 in conventional high-throughput screening,… Read More about 100 AI-generated molecules are worth a 1,000,000 molecule high-throughput screen
Applicability domains are common in QSAR but irrelevant for conventional ML tasks
Traditional QSAR models are limited to interpolation within known chemical spaces, restricting drug discovery. In contrast, modern machine learning excels at extrapolation, opening new possibilities for exploring untapped chemical compounds… Read More about Applicability domains are common in QSAR but irrelevant for conventional ML tasks
Variational AI announces generative AI project with Merck
Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program. Read More about Variational AI announces generative AI project with Merck
Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI
Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents… Read More about Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI
Variational AI Adds Jennifer Hamilton as Advisor
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor. Read More about Variational AI Adds Jennifer Hamilton as Advisor
Variational AI Adds Leading Oncology Researchers to Scientific Advisory Board
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leaders Dr. John F. Boylan and Dr. Mads… Read More about Variational AI Adds Leading Oncology Researchers to Scientific Advisory Board
